The underlying premise at Back Bay Life Science Advisors is that any accurate asset or company valuation must be derived from a fundamental understanding of the scientific, clinical, and commercial aspects of the financial models in use. Disciplined deal-making also considers external factors: the specific strategic fit and competitive intensity regarding any company or asset. For all these reasons, we deploy several methodologies to evaluate clinical-stage programs.Read more »
A new article by Back Bay Senior Associate and life science transaction advisory expert, James Leech, brings insight to cross-border funding in the life sciences.
In the current issue of Pharmaceutical Executive, The State of Cross-Border Funding in the Life Sciences describes record capital flow across global markets that have opened new channels of investment in early-stage and novel science. While the U.S. remains fertile ground for investable life science opportunities and continues to be a target capital source for emerging companies, Mr. Leech writes: Read more »
Biotech and Pharma Leaders to Convene in California Oct. 5-7 to Discuss Top Trends in Biopharma Partnering
BioNetwork West, Sponsored by Back Bay Life Science Advisors, to Highlight New Technologies, Innovations
BOSTON, September 26, 2016 – The nation’s leading biotech and pharma leaders will convene October 5-7 to discuss top trends at the BioNetwork Partnering Summit in Laguna Niguel, California.
Jonathan P. Gertler, MD, managing partner and CEO of Back Bay Life Science Advisors (Back Bay), will serve as event chairperson and will be joined by other members of Back Bay leadership who will moderate key panel discussions around successful business development in the life sciences. For the second year, Back Bay, which provides leading life science companies with strategic guidance and transactional advisory services, will serve as lead sponsor of the event.
Read more »